# Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

> **NCT02396043** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma, Lymphoblastic

## Interventions

- **DRUG:** induction phase1
- **DRUG:** induction phase2
- **DRUG:** protocol M
- **DRUG:** maintenance therapy
- **DRUG:** reinduction phase1
- **DRUG:** reinduction phase2
- **DRUG:** Intrathecal (IT)

## Key facts

- **NCT ID:** NCT02396043
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396043, "Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02396043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*